High-dose chemotherapy (CHT) and autologous stem cell The aim of the study was to retrospectively evaluate the transplantation (ASCT) were first employed in the treatoutcome of patients with aggressive non-Hodgkin's lymment of resistant or relapsed intermediate-and high-grade phoma (NHL), undergoing autologous stem cell transnon-Hodgkin's lymphomas (NHL) in the late 1970s.
serum lactate dehydrogenase (LDH) greater than normal, radiographs). Performance status was assessed according to the Eastern Cooperative Oncology Group (ECOG) scale. 21 poor performance status, Ann Arbor stage III-IV and the number of extranodal sites of disease (only Ann Arbor Prediction of relative risk of death was retrospectively evaluated using the age-adjusted IPI 14 based on tumor stage, LDH and performance status in the age-adjusted version of the index, for people younger than 60 years) as the stage, LDH and performance status. A detailed history was taken from all patients and all most accurate pretreatment clinical features predictive of overall survival and relapse-free survival. The IPI was underwent physical examination, routine blood tests, serology for HBV, HCV and HIV infections, chest radiographs, developed through a collaborative international effort, was subsequently validated by others on patients with all grades computed tomography (CT) scans of chest and abdomen, and bone marrow aspirate and biopsy. Other examinations of malignancy, [15] [16] [17] and is currently widely accepted as the prognostic factor model for patients with NHL. Since were performed as clinically indicated. All patients with bulky disease were also entered on an ongoing study com-ASCT for NHL at or before first CR must still be considered experimental, it has been suggested that only paring CT, magnetic resonance imaging (MRI), and 67
Gallium-scintigraphy ( 67 GA-S) for the evaluation of patients with a prediction of poor outcome as by the IPI (those in the high-intermediate and high-risk groups) residual mass after therapy. 23 Thirteen patients underwent surgery for diagnostic and/or should be selected for this therapeutic approach as part of their initial treatment. [18] [19] [20] de-bulkying purposes (one thyroidectomy, two splenectomies, one partial hepatectomy, seven GI tract and two The real impact on survival of ASCT in patients selected on the basis of the IPI is currently unknown and needs to mediastinum), and one patient underwent RT on the dorsolumbar spine (for the presence of lymphoma in that site), be prospectively evaluated.
We report our experience on a series of 52 consecutive as the first therapeutic intervention. All patients then underwent chemotherapy: six patients with lymphoblastic patients with aggressive NHL, who were autotransplanted at our institution immediately after attaining a first response lymphoma underwent CHT according to the ALL 0288 protocol 24 (a sequential acute lymphoblastic leukemia-type (complete or partial). They were retrospectively reclassified according to the IPI and their outcomes were evaluated in protocol), while all the other patients (46) In 10 patients RT was then performed (after CHT) on residual mediastinal disease. After completing first-line high-grade NHL, considered as having a high-risk disease according to our definition (presence of at least one of the therapy (CHT Ϯ RT), the response was consolidated with ASCT in all patients. In 32 patients the source of hemofollowing adverse prognostic features: bulky disease, B symptoms or Ann Arbor stage III-IV). After first-line therpoietic progenitors was BM. The last 20 patients were harvested from the BM (11) or from the PB (9) after in apy (CHT Ϯ RT), patients were selected for the intensive regimen only if they had attained at least a partial remission vivo priming with G-CSF as part of a randomized trial comparing filgrastim-primed BM transplantation vs filgrastimand if they had a good performance status (0-1 according to the ECOG scale). 21 Patients with the same histology but mobilized PB transplantation. 28 A single BM harvest or three PB aphereses were performed to collect the necessary without adverse prognostic features or patients with disease resistant to first-line therapy were excluded from this number of stem cells. Harvested BM and PB were processed on a Fenwall CS 3000 Separator (Baxter Health analysis.
Diagnosis was performed on pathologic specimens (fixed Care Products, Deerfield, IL, USA) and the MNC were cryopreserved in 20% DMSO with 50% autologous plasma in 10% buffered formalin, processed using routine techniques and embedded in paraffin) and was based on morand kept at Ϫ196°C. The conditioning regimen used was BAVC, 29 22 is also provided in once daily, all from day Ϫ5 to day Ϫ2. Patients were treated in private rooms with reverse isolation and a diet Table 1 .
Staging was defined according to the Ann Arbor criteria. low in bacteria and fungi. Antimicrobical, antifungal, and antiviral prophylaxis consisted of oral co-trimoxazole or Bulky disease was defined as the presence of a mass у10 cm in diameter; bulky mediastinum was defined as a MT ciprofloxacin, itraconazole, nystatin or amphotericin suspension, and acyclovir, respectively. Parenteral antibiotics ratio у0.33 (MT ratio = the ratio between the maximum mediastinal diameter and the maximum thoracic diameter at were started after onset of fever у38°C during neutropenia and maintained until the patient was apyrexial for at least level T5-T6, as detected by standard posteroanterior chest After reinfusion all patients received granulocyte colonycases, with bone marrow involvement in only five patients and no cases of CNS involvement. Of the eight patients stimulating factor (G-CSF; Filgrastim) from day +4 until attaining a neutrophil count exceeding 1 ϫ 10 9 /l for 3 conwith gastrointestinal involvement, seven were in stage IV and one in stage I E . Bulky disease was detected in 67.3% secutive days, as described elsewhere. 28 Patients were routinely restaged after CHT, after RT, 3 of cases, with mediastinal involvement accounting for the majority. Relative risk of death according to the agemonths after ASCT, then at 6 monthly intervals for 2 years and yearly thereafter. bodies, and anti-HBV was present in only one patient. When an obvious (greater than 80%) reduction but not complete disappearance of the original bulky mass was observed (a lesion у2 cm in diameter detectable on CT), Transplant-related data the patient was retrospectively considered to be in CR only if repeated CT scans did not shown deterioration over the Table 3 shows the main transplant-related data. At a median next 2 years, and MRI and 67 GA-S was recorded as of 3 months (1-9) from the end of CHT, patients underwent negative.
bone marrow or peripheral blood harvest, with no patient Partial remission (PR) was defined as a reduction in having bone marrow involvement by the disease at that tumor mass of at least 50%, and resistance (R), as a time. They were autotransplanted after a median of 3 reduction in tumor mass of less than 50%. months (0.5-10) from harvest, with 49% being reinfused The CR rate, overall survival and disease-free survival within 12 months from diagnosis (25/51; one patient was observed after sequential treatment (CHT Ϯ RT + ASCT), never reinfused since she died during conditioning). A as opposed to those expected after CHT according to the median of 0.45 (0.19-1.9) ϫ 10 8 BM MNC/kg b.w. or 5.3 IPI, were compared for each risk group using the 2 Yates-(1.0-7.8) ϫ 10 8 PB MNC/kg b.w. were reinfused. corrected test. All P values are two tailed.
Engraftment was observed in all. Median time to у0.5 and у1.0 ϫ 10 9 /l PMN was 13 (8-22) and 13 (8-42) days, respectively; median time to у20 and у50 ϫ 10 9 /l PLT Results was 14 (7-22) and 16.5 (10-57) days, respectively. A median of 4 (0-14) blood units and 4 (1-12) PLT aphereses Patients were transfused. Patients received a median of 11 doses of G-CSF (range 6-19) after transplant and all tolerated GHistologic diagnoses are given in Table 1 . The histologic patterns of the four MALT and the six follicular CSF administration with no problems. In 34 patients (65.3%) a febrile episode was documented lymphomas were consistent with intermediate-high-grade disease. General characteristics of the patients and clinical in the period of post-transplant aplasia: 10 (29.4%) were Gram+ septicemias, only two (5.9%) GramϪ septicemia, features at presentation are given in Table 2 . There was a male prevalence (53.8%), with a median age of 40 years three (8.8%) were associated with herpes virus oral mucositis and the other 19 (55.9%) had fever of unknown origin. (15-57) and only four patients under the age of 18 and three over the age of 55. Eighty-three percent of patients Median duration of fever was 5 days (1-19)/febrile patient; median duration of antibiotic therapy was 9 days (5-were ambulatory (PS 0-1); 65.4% of cases presented with advanced stage (III and IV) disease with only four patients 24)/febrile patient; median hospitalization time was 18 days (11-32) from reinfusion. in stage I (bulky liver, colon, spleen and breast disease, Table 2 Clinical features at diagnosis of the 52 patients reached the criteria for being considered in CR. Table 4 shows response during sequential treatment. After Four major toxic events were recorded. A 31-year-old female patient with anaplastic large cell lymphoma (ALCL) CHT, 33 patients (64.7%) reached a CR: 16 (30.7%) patients were partial responders with a residual mediastinal died of pulmonary vein thrombosis during conditioning. She was in PR with a residual mediastinal mass, which was (nine), retroperitoneal (two), mediastinal and retroperitoneal (one), mediastinal and hepatic (one), abdominal shown on autopsy to compress the pulmonary vein. A second patient, a 45-year-old male with ALCL, who had (one), lung (one) or splenic (one) mass, and three patients (5.7%) with mediastinal disease were considered resistant previously undergone CHT and RT to a residual mediastinal mass, developed symptomatic heart failure soon after to CHT.
Major toxic events Disease response
In 10 cases (seven in PR and three resistant) with a diagtransplant. He is currently in CR with a stable cardiac condition (although on chronic medication). A third patient, a nosis of diffuse large cell lymphoma and a residual mediastinal disease, involved-field RT was performed, allowing 40-year-old male with ALCL, developed an immune throm-267 Table 4 Analysis of response during sequential treatment bocytopenic purpura 32 months after transplant while in this progressively increased to 14% (P = 0.01) in the LI, 23% (P Ͻ 0.0001) in the HI and 54% (P Ͻ 0.0001) in the CR. Finally, a 54-year-old female with lymphoblastic lymphoma previously treated with CHT, harvested from PB H risk group patients, respectively. Table 6 shows the advantage of sequential treatment with after priming with G-CSF, and reinfused with 5.3 × 10 8 MNC/kg b.w., while in CR developed a secondary acute ASCT in terms of OS and DFS. The 2-year OS advantage was 10% (P = 0.0035), 21% (P Ͻ 0.0001), 31% (P Ͻ myeloid leukemia 6 months after transplant. She was treated for high-risk acute leukemia and is currently alive 0.0001) and 63% (P Ͻ 0.0001), respectively in the four risk groups; and the 2-year DFS advantage was 12% (P = and in CR.
0.0010), 26% (P Ͻ 0.0001), 38% (P Ͻ 0.0001) and 39% (P Ͻ 0.0001), respectively, Even more striking are the 5-Outcome year projected advantages. Considering only the lower (L + LI) risk groups, the real percentage of patients alive As at March 1997, 47/52 patients (90.4%) are in CR. The actuarial overall survival (OS), from diagnosis, is 98.1% at without disease at 5 years (as expected by the IPI) is 79.1% (86% of the 92% in CR) in the L risk group and only 51.5% a median of 37 months (16-88); and the actuarial diseasefree survival (DFS), calculated from the time of CR, is (66% of the 78% in CR) in the LI risk group. In our cohort of patients, the 5-year projected percentage of patients alive 100% at a median of 27 months (7-82). Twenty-seven out of 51 (52.9%) patients have been transplanted, and 27/47 without disease is 92% for both groups (P Ͻ 0.0001). (57.4%) entered a CR, more than 24 months prior to this evaluation.
In Table 5 , response to the sequential treatment has been Discussion analyzed according to the age-adjusted IPI. The CR rate after CHT was in line with that expected for the LI and HI One of the major issues concerning the role of myeloablative therapy and ASCT at or before first CR is transplantrisk groups, being lower (58 vs 92%) for the L risk group and higher (60 vs 46%) for the H risk group. Three patients related morbidity and mortality in patients who may already be cured. Moreover, three major randomized studies have (in the L, HI and H risk groups, respectively) entered CR after RT, while another 11 patients (three, five, two and compared conventional-dose CHT vs ASCT in NHL in first remission, and in none of them was a significant difference one in the L, LI, HI and H risk groups, respectively) entered CR only after ASCT.
in favour of ASCT found. [30] [31] [32] On the other hand, the following observations favour high-dose CHT and ASCT at In terms of CR rate, the sequential treatment including ASCT did not give any advantage, as compared with CHT or before first CR: (1) the transplant-related mortality is currently well below 5% and can be defined as (the difference between the actually observed CR rate and that expected after CHT), in the L risk group patients, but occasional; 29, 33 (2) a high relapse rate occurs in patients treated with CHT only, (approximatively 50%); 14 (3) the stantial toxicity if they are treated with ASCT. There are already some initial results of studies showing an advantage development of cytotoxic drug resistance is prevented if effective treatment is given early in the course of the in terms of OS and DFS in favour of ASCT for patients in the HI and H risk groups reported in the literature. 19, 20, 46 disease; 34 (4) status at transplant is the most important prognostic factor predicting overall and progression-free
Haioun et al, 31 for instance, showed no advantage of ASCT when all patients were considered together, but subsurvival, with patients transplanted in first CR doing better than any other group (for both diffuse large cell and sequently they showed a significant advantage for those in the H and HI risk groups, when stratified for this characterlymphoblastic lymphomas); 18, 35, 36 and (5) single center, non-randomized studies showed the best survivals and istic. 46 The outcome of patients in the L risk group is very good even with CHT only (92% CR rate, 90 and 88% 2 progression-free survivals for patients autotransplanted in first CR for both diffuse large cell 20 and lymphoblastic years and 83 and 86% 5 years OS and DFS, respectively) and seems unlikely to be improved using the more intensive lymphomas.
37-40
These figures appear to be in excess of what would be approach; but the outcome of patients in the LI risk group (78% CR rate, 79 and 74% 2 years and 69 and 66% 5 years expected from a group of patients with de novo NHL treated with standard CHT.
OS and DFS, respectively) is, in our opinion, likely to be improved: ASCT might improve the outcome of these Although the use of ASCT is still controversial at or before first CR, it appears to be the best option for those patients by increasing CR percent (transforming PR in CR) and by reducing relapse rate. patients achieving only PR (10-50% of patients with aggressive NHL) to front-line therapy, where the outcome In our cohort of patients, the expected CR rate after CHT (Table 5 ) was in line with what was expected only for the is poor even with the use of intensive second or third generation salvage regimens, 41 especially if dose-intensive LI and HI risk groups. It was higher in the H risk group and this was probably due to the low number of patients therapy is initiated before disease progression: early introduction of ASCT in patients with PR may offer the potenanalyzed in this group, and it was lower in the L risk group. This could be explained by the presence in this group of tial to cure this group of patients. [42] [43] [44] [45] With this background we started our NHL transplant profive stage II patients (four with bulky mediastinum and one with bulky retroperitoneal disease) who were defined only gram in 1990, with the aim of submitting all patients with high-risk disease to ASCT in first remission (complete or as partial responders (four) or resistant (one) after CHT. It should be pointed out that the evaluation of response in our partial). Since our definition of high-risk was based in part on those risk factors known at that time to be predictors patients was very accurate, and was performed using three highly sophisticated imaging techniques (CT, MRI and of poor outcome, we have now reanalyzed our cohort of transplanted patients in view of the recently proposed IPI, 67 GA-S). As a consequence, the probability that some patients in CR were considered as PR was very low; howin its age-adjusted version. The identification of high-risk patients (those in the HI and H risk groups) might have ever, many cases that could have been considered as CR if restaged with traditional techniques or even with CT scans important therapeutic implications since these patients are not effectively treated with current CHT regimens and are only, are currently considered as PR. 23 This improvement in the evaluation of residual masses after therapy implies most likely to benefit from consolidation therapy with ASCT programmed as part of their initial treatment. On the that those patients with a marked reduction but not complete disappearance of the original mass and signs of active other hand, low-risk patients (those in the L and LI risk groups) may do well with standard therapy and incur subdisease on MRI and 67 GA-S, must be considered as partial responders to CHT and therefore candidates for radiotial therapy which includes CHT Ϯ RT and ASCT is safe, allowing a greater proportion of complete remissions, mititherapy and consolidation with ASCT.
Our observations would also suggest a role for involved gating against early relapse as seen after treatment with CHT only, and suggesting that these patients may be longfield RT in the treatment of residual mediastinal disease before ASCT. In fact, three out of seven partial responders term survivors. The question concerning whether only patients with HI or H risk disease will benefit from this entered CR after RT and the three resistant patients became partial responders. approach, cannot be answered at present. The differences seen in this study suggest that a formal Nevertheless, even after RT, around 30% of our patients did not reach CR and, as mentioned before, the outcome comparison in a randomized study may also be appropriate for patients in the lower risk groups, at least for those in of partial responders is very poor if not treated with highdose CHT and ASCT. 41 With the use of this therapeutic the LI risk group. Meanwhile, it is mandatory that the International Prognostic Index be reported in all scientific comapproach our CR rate increased overall from 69.2 to 90.4%, with a conversion of partial responders to complete munications, in order to better define its prognostic implications for patients undergoing autotransplant. responders of more than 70% (11 out of 15). Comparing the observed CR rate obtained after ASCT with that expected after CHT, the relative increase observed for all risk groups except the L, was progressively greater as riskIn our cohort of patients the 2-year OS is 98.1% with an In conclusion, within the limits of a small, single center 1628-1637. series, our study supports the concept that the outcome of 
